Howard West
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 104
- Lung Cancer Diagnosis and Treatment 37
- Gastric Cancer Management and Outcomes 7
- Oncology 90
- Lung Cancer Research Studies 36
- Colorectal Cancer Treatments and Studies 26
- Cancer Immunotherapy and Biomarkers 17
- Co-authors
- Bradley T. Hyman (7 shared papers)Teresa Gómez‐Isla (5 shared papers)John H. Growdon (5 shared papers)David R. Gandara (21 shared papers)Stina Mui (3 shared papers)Joseph E. Parisi (1 shared paper)Ronald C. Petersen (1 shared paper)Richard Hollister (2 shared papers)
- Journals
- Journal of Clinical Oncology (43 papers)JAMA Oncology (32 papers)Journal of Thoracic Oncology (20 papers)Annals of Oncology (16 papers)Clinical Lung Cancer (8 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Howard West
186 papers receiving 8.5k citations
Howard West's Hit Papers
Peers
Comparison fields: 5 of 150
- Oncology 3.7k
- Pulmonary and Respiratory Medicine 4.0k
- Physiology 1.4k
- Cancer Research 712
- Neurology 312
Countries citing papers authored by Howard West
This map shows the geographic impact of Howard West's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard West with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard West more than expected).
Fields of papers citing papers by Howard West
This network shows the impact of papers produced by Howard West. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard West. The network helps show where Howard West may publish in the future.
Co-authors
The 25 scholars most cited alongside Howard West, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 191 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1170 |
| 2 | Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease Hit paper breakdown → | 1997 | 1153 |
| 3 | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Hit paper breakdown → | 2014 | 541 |
| 4 | Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study Hit paper breakdown → | 2005 | 493 |
| 5 | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial Hit paper breakdown → | 2015 | 464 |
| 6 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Hit paper breakdown → | 2017 | 433 |
| 7 | 1996 | 322 | |
| 8 | Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial Hit paper breakdown → | 2020 | 300 |
| 9 | 2007 | 231 | |
| 10 | 2014 | 217 | |
| 11 | 2019 | 215 | |
| 12 | 1995 | 168 | |
| 13 | 2015 | 163 | |
| 14 | 1994 | 148 | |
| 15 | 2006 | 114 | |
| 16 | 2018 | 112 | |
| 17 | 1994 | 110 | |
| 18 | Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Hit paper breakdown → | 2023 | 107 |
| 19 | 2019 | 101 | |
| 20 | 2022 | 99 |
About Howard West
Howard West is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 191 papers that have together received 8.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (104 papers), Lung Cancer Diagnosis and Treatment (37 papers), Lung Cancer Research Studies (36 papers), Colorectal Cancer Treatments and Studies (26 papers), Cancer Genomics and Diagnostics (25 papers), Cancer Immunotherapy and Biomarkers (17 papers), Gastric Cancer Management and Outcomes (7 papers) and Alzheimer's disease research and treatments (7 papers). The work is most often cited by research in Oncology (3.7k citations), Pulmonary and Respiratory Medicine (4.0k citations), Physiology (1.4k citations), Cancer Research (712 citations) and Neurology (312 citations). Howard West has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Bradley T. Hyman, Teresa Gómez‐Isla, John H. Growdon, David R. Gandara, Stina Mui, Joseph E. Parisi, Ronald C. Petersen, Richard Hollister, G. William Rebeck and Jill Jin. Their work appears in journals such as Journal of Clinical Oncology, JAMA Oncology, Journal of Thoracic Oncology, Annals of Oncology and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.